The company said its diagnostic product identified more than double the number of patients who may benefit from treatment with niraparib than were identified by germline BRCA testing alone.
Germline BRCA testing can inform treatment decisions and identify women with ovarian cancer who could benefit from risk reduction strategies.
The myChoice HRD test was evaluated in the NOVA study (NCT01847274) of nirarapib, an investigational oral PARP inhibitor being developed by TESARO Inc (NASDAQ:TSRO).
Myriad’s proprietary HRD test detects when a tumor has lost the ability to repair double-stranded DNA breaks resulting in increased susceptibility to DNA-damaging drugs.
“Patients with ovarian cancer who tested positive with myChoice HRD experienced a clinically meaningful improvement in PFS [progression-free survival],” said Johnathan Lancaster, MD, PhD, gynaecological oncologist and chief medical officer of Myriad Genetic Laboratories.
“We estimate that myChoice HRD identifies more than double the number of patients who may benefit compared to germline BRCA testing alone,” he added.
The NOVA results showed that in patients who were germline BRCA mutation carriers, the median PFS for patients treated with niraparib was 21.0 months compared to 5.5 months for the control group.
Story by ProactiveInvestors